CrossRef Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Wonseok Kang, Gi-Ae Kim, Hyung Joon Kim, Yun Bin Lee, Jeong-Hoon Lee, Neung Hwa Park, So Young Kwon, Soo Young Park, Ji Hoon Kim, Gwang Hyeon Choi, Eun Sun Jang, Chien-Hung Chen, Yao-Ch The Lancet Gastroenterology & Hepatology .2025
Semaglutide, also known by the brand names Ozempic, Rybelsus and Wegovy, is an FDA-approved once-weekly GLP-1 receptor agonist manufactured by Novo Nordisk
If you experience any adverse effects, you can report them through the MHRA Yellow Card scheme
The short answer is: not necessarily, but it depends on your individual circumstances